99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect...
- Mechanism
- Curator reviewed
The 99mTc 14F7 Mab has shown to bind specifically to GM3 (NeuGc) and that it also reacts with human breast and melanoma tumors in contrast with its low reactivity in normal tissues. N-Glycolyl GM3 is considered a heterophilic antigen since is not present in all species, humans are normally lacking them. The discovery of the presence of this molecule in significant amounts in breast tumors allowed considering it as an advantageous target for cancer immunotherapy.
- Primary indication
- Investigated for use/treatment in breast cancer.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with 99mTc-14 F7 Mab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account